QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
Go back to QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups| Qiagen NV (NYSE: QGEN) | Delayed: 36.95 +0.37 (1.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.58 | 52 Week High | $28.50 | |||
| Open | $36.24 | 52 Week Low | $19.94 | |||
| Day High | $37.06 | P/E | 127.41 | |||
| Day Low | $36.19 | EPS | $0.29 | |||
| Volume | 1,964,098 | |||||
| (NYSE: QIA) | Delayed: 0.00 -10.35 (100%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.35 | 52 Week High | $ | |||
| Open | $10.35 | 52 Week Low | $ | |||
| Day High | $10.35 | P/E | N/A | |||
| Day Low | $10.35 | EPS | $ | |||
| Volume | 0 | |||||

